{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:20Z","timestamp":1790217380552,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/iae.0b013e318296e26d","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T11:18:32Z","timestamp":1372245512000},"page":"77-82","source":"Crossref","is-referenced-by-count":45,"title":["COMBINED INTRAVITREAL BEVACIZUMAB INJECTION AND ZONE I SPARING LASER PHOTOCOAGULATION IN PATIENTS WITH ZONE I RETINOPATHY OF PREMATURITY"],"prefix":"10.1097","volume":"34","author":[{"given":"Jaeryung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Sil","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Soon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1091-8531(99)70091-1","article-title":". Childhood blindness.","volume":"3","author":"Steinkuller","year":"1999","journal-title":"J AAPOS"},{"key":"R2-11-20210130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/IAE.0b013e3181cb6151","article-title":"Aggressive posterior retinopathy of prematurity.","volume":"30","author":"Drenser","year":"2010","journal-title":"Retina"},{"key":"R3-11-20210130","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity clinical characteristics and treatment outcomes.","volume":"26","author":"Kychenthal","year":"2006","journal-title":"Retina"},{"key":"R4-11-20210130","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","article-title":"Outcome of zone I retinopathy of prematurity.","volume":"81","author":"OKeefe","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"R5-11-20210130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0161-6420(00)00436-X","article-title":"The outcome of retinopathy of prematurity.","volume":"108","author":"Onofrey","year":"2001","journal-title":"Ophthalmology"},{"key":"R6-11-20210130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10384-004-0216-2","article-title":"The effect of early treatment at the initial stage 3 moderate phase of retinopathy of prematurity on severe retinal changes.","volume":"49","author":"Hatsukawa","year":"2005","journal-title":"Jpn J Ophthalmol"},{"key":"R7-11-20210130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-11-20210130","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatmenta review.","volume":"100","author":"Hard","year":"2011","journal-title":"Acta Paediatr"},{"key":"R9-11-20210130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaapos.2011.11.002","article-title":"Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both J","volume":"16","author":"Avery","year":"2012","journal-title":"AAPOS"},{"key":"R10-11-20210130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":". Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R11-11-20210130","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity.","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med"},{"key":"R12-11-20210130","first-page":"170","article-title":"Ewald U, et al..","volume":"91","author":"Spandau","year":"2013","journal-title":"Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity Acta Ophthalmol"},{"key":"R13-11-20210130","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":". Reactivation of retinopathy of prematurity after bevacizumab injection.","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R14-11-20210130","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":". Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R15-11-20210130","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","article-title":". Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels.","volume":"248","author":"Lee","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R16-11-20210130","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","article-title":". Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.","volume":"248","author":"Nazari","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R17-11-20210130","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1542\/peds.2005-2749","article-title":"Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity.","volume":"117","year":"2006","journal-title":"Pediatrics"},{"key":"R18-11-20210130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajo.2004.12.106","article-title":". Involution of retinopathy of prematurity after laser treatment: factors associated with development of retinal detachment.","volume":"140","author":"Coats","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R20-11-20210130","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":". Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-11-20210130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":". Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan.","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"R22-11-20210130","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","article-title":"Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).","volume":"30","author":"Dorta","year":"2010","journal-title":"Retina"},{"key":"R23-11-20210130","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"R24-11-20210130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":". Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.","volume":"14","author":"Law","year":"2010","journal-title":"J AAPOS"},{"key":"R25-11-20210130","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0161-6420(03)01004-2","article-title":"Safe and effective.","volume":"110","author":"Schachat","year":"2003","journal-title":"Ophthalmology"},{"key":"R26-11-20210130","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":". Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"R27-11-20210130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"R28-11-20210130","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI10259","article-title":". Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.","volume":"106","author":"Kasahara","year":"2000","journal-title":"J Clin Invest"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0b013e318296e26d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T01:31:15Z","timestamp":1715563875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201401000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e318296e26d","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}